Sygnature Discovery and Pneumolabs have entered into a strategic alliance to provide a fully-integrated drug discovery service aimed at accelerating clients’ drug discovery programs into development. The alliance complements Sygnature’s existing partnership with Cyprotex Discovery, a center of excellence for in vitro ADME/toxicology, and Saretius, a preclinical experimental services company offering techniques in pain, metabolic and CNS disorders, inflammatory disease and in vivo pharmacokinetics.
 
Dr. Phillip Gardiner, chief executive officer at Pneumolabs, said, “We are pleased to have entered into a strategic alliance with Sygnature Discovery. Our strategic alliance combines the complementary skills of Pneumolabs, a centre of excellence for respiratory disease-focused preclinical research services, and Sygnature, a centre of excellence for medicinal chemistry-driven integrated drug discovery. Working closely together on respiratory disease-focused discovery projects, we are confident that Pneumolabs and Sygnature can advance clients’ programs more quickly and effectively.”
 
Dr. Simon Hirst, Sygnature’s chief executive officer, said, “Pneumolabs has gained an excellent reputation as a contract research company which provides high quality preclinical research services focused on respiratory diseases. The close working relationship that we have already established with Pneumolabs will be cemented through this new strategic alliance. This powerful combination of alliance partners will help advance our clients’ respiratory-focused drug discovery programs towards development more efficiently.”